The DOI matches its Crossref record; 117 of the 119 references it cites were found in a registry or an index.
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Open accessAbstract
Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of beta-amyloid (Abeta) peptide, ultimately leading to formation of Abeta plaques in the brain. This process occurs while individuals are still cognitively normal. Biomarkers of brain beta-amyloidosis are reductions in CSF Abeta(42) and increased amyloid PET tracer retention. After a lag period, which varies from patient to patient, neuronal dysfunction and neurodegeneration become the dominant pathological processes. Biomarkers of neuronal injury and neurodegeneration are increased CSF tau and structural MRI measures of cerebral atrophy. Neurodegeneration is accompanied by synaptic dysfunction, which is indicated by decreased fluorodeoxyglucose uptake on PET. We propose a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers become abnormal later, and correlate with clinical symptom severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These investigations have established that volumetric decline occurs initially in medial temporal lobe grey matter, following tau protein deposition, and is closely correlated to cognitive decline.”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the regional level, abnormality is evident in medial temporal lobe areas first (hippocampus and entorhinal cortex), then in lateral temporal lobe areas (mid-temporal gyrus and fusiform gyrus) and finally in frontal lobe areas (Jack Jr. et al 2010, Young et al 2014).”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because measures of all biomarkers studied to date have considerable overlap with those found other types of dementia (as well the cognitively normal elderly population), it remains difficult to determine whether or not cognitive impairment is due to AD or another more dominant and concurrent process.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it is Tau pathology and synapse loss that temporally correlate with cognitive impairment and precede overt neurodegeneration (Jack et al., 2010; Scheff et al., 2006; Spires-Jones and Hyman, 2014”
From Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies (2018) · cites this paper as Jack et al., 2010
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“Firstly, cognitive decline is more closely correlated to neurodegeneration than tau accumulation (Jack Jr. et al 2010).”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
The cited source says what the claim attributes to it.
In the citing paper
“Alzheimer’s disease (AD) is characterized by deposition of hallmark pathological peptides and neurodegeneration that progress across partially overlapping neuroanatomical and temporal axes1,2.”
From Integrated multimodal cell atlas of Alzheimer’s disease (2024) · cites this paper as [2]
In the citing paper
“Autosomal dominant mutations to the MAPT (tau) gene lead to neuronal tangle pathology and frontotemporal dementia but not to amyloid plaques 122,123 , suggesting that tau pathology does not induce Aβ pathology.”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [123]
In the citing paper
“Amyloid plaques appear a decade or two before clinical symptoms of AD, but it is tau pathology and synapse loss that correlate best with cognitive impairment during disease progression (Jack et al., 2010).”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Jack et al., 2010
In the citing paper
“Extensive biomarker and imaging studies indicate that amyloid-β aggregation is the earliest pathological event in Alzheimer’s disease, followed at a later stage by pathological changes of tau aggregation extending beyond the limbic system to the neocortex, which correlates with brain atrophy and cognitive decline2,3.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [2]
In the citing paper
“Their timeline states that in individuals who develop AD, Aβ plaque deposition and reduced CSF Aβ occur first. Next, CSF tau levels rise. These changes manifest years before clinical signs or symptoms develop. Later on hippocampal atrophy appears, followed shortly thereafter by memory decline and eventually dementia. Full progression from Aβ changes to clinical decline takes approximately 10 to 20”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“data argue symptoms generally manifest only after plaques stop forming (Figure 5) [205, 216, 217].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“As people meeting preclinical AD criteria may remain cognitively stable for many years [205, 214], these trials will take a long time to complete.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“The new AD biological framework and the model of pathologic AD biomarkers from Jack and colleagues 18 conceptualize a progressive sequence of measurable biochemical, neurophysiological, and neuroanatomical alterations that can be detected years before psychometrically and clinically noticeable deterioration in cognition, behavior, and function.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [18]
In the citing paper
“The neuropathological changes that are quintessential for AD diagnosis—namely, the development of amyloid plaques and tau tangles—are considered to develop years before onset of the cognitive changes that characterize AD dementia [26].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Interplay between Cortical Spreading Depolarization and Seizures
Kramer, D. R., Fujii, T., Ohiorhenuan, I. E., & Liu, C. Y. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000452841 · Cited by 3,721
Cited by
Sorted by citations
Items 401–500 of 1,077
Beta-amyloid imaging with florbetaben
Sabri, O., Seibyl, J. P., Rowe, C. C., & Barthel, H. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-015-0102-6 · Cited by 177
Associations between recent and established ophthalmic conditions and risk of Alzheimer's disease
Lee, C. S., Larson, E. B., Gibbons, L. E., Lee, A., McCurry, S. M., Bowen, J. D., McCormick, W. C., & Crane, P. K. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2856 · Cited by 178
Brookmeyer, R., & Abdalla, N. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.03.005 · Cited by 176
Reactive astrocytes in Alzheimer’s disease: A double-edged sword
Chun, H., & Lee, C. J. (2018) · Neuroscience Research · doi:10.1016/j.neures.2017.11.012 · Cited by 176
Chirles, T. J., Reiter, K. E., Weiss, L. R., Alfini, A. J., Nielson, K. A., & Smith, J. C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161151 · Cited by 176
Role of mitochondrial homeostasis and dynamics in Alzheimer's disease
Selfridge, J. E., E, L., Lu, J., & Swerdlow, R. H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.057 · Cited by 175
Buckley, R., Saling, M. M., Ames, D., Rowe, C. C., Lautenschlager, N. T., Macaulay, S. L., Martins, R. N., Masters, C. L., O'Meara, T., Savage, G., et al. (2013) · International Psychogeriatrics · doi:10.1017/s1041610213000665 · Cited by 173
More than a marker: potential pathogenic functions of MAP2
DeGiosio, R. A., Grubisha, M. J., MacDonald, M. L., McKinney, B. C., Camacho, C. J., & Sweet, R. A. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.974890 · Cited by 173
Cortical iron reflects severity of Alzheimer's disease
van Duijn, S., Bulk, M., van Duinen, S. G., Nabuurs, R. J. A., van Buchem, M. A., van der Weerd, L., & Natté, R. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161143 · Cited by 172
“A promising approach is in vivo detection of amyloid β (Aβ) plaques, neuropil threads (NT) and neurofibrillary tangles (NFT), since these histological hallmarks of AD occur 10-20 years before cognitive decline [1, 2].”
BackgroundResultIrwin, D. J., Abrams, J. Y., Schonberger, L. B., Leschek, E., Mills, J. L., Lee, V. M. ‐., & Trojanowski, J. Q. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1933 · Cited by 172
Self-citationBACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease
Barão, S., Moechars, D., Lichtenthaler, S. F., & De Strooper, B. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.01.003 · Cited by 158
Nec‐1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice
Yang, S., Lee, D. K., Shin, J., Lee, S., Baek, S., Kim, J., Jung, H., Hah, J., & Kim, Y. S. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606566 · Cited by 172
Microinfarcts, brain atrophy, and cognitive function: The Honolulu Asia Aging Study Autopsy Study
Launer, L. J., Hughes, T. M., & White, L. R. (2011) · Annals of Neurology · doi:10.1002/ana.22520 · Cited by 171
Cerebral atrophy in mild cognitive impairment and Alzheimer disease
Leung, K. K., Bartlett, J. W., Barnes, J., Manning, E. N., Sebastien Ourselin, A., Fox, N. C., & Initiative, A. D. N. (2013) · Neurology · doi:10.1212/wnl.0b013e318281ccd3 · Cited by 171
Interaction between blood-brain barrier and glymphatic system in solute clearance
Verheggen, I. C. M., van Boxtel, M. P. J., Verhey, F. R. J., Jansen, J. F. A., & Backes, W. H. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.028 · Cited by 171
Patterns of functional connectivity in an aging population: The Rotterdam Study
Zonneveld, H. I., Pruim, R. H. R., Bos, D., Vrooman, H. A., Muetzel, R. L., Albert Hofman, D., Rombouts, S. A. R. B., van der Lugt, A., Niessen, W. J., Ikram, M. A., et al. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.01.041 · Cited by 171
SPECT and PET imaging in Alzheimer’s disease
Valotassiou, V., Malamitsi, J., Papatriantafyllou, J., Dardiotis, E., Tsougos, I., Psimadas, D., Alexiou, S., Hadjigeorgiou, G., & Georgoulias, P. (2018) · Annals of Nuclear Medicine · doi:10.1007/s12149-018-1292-6 · Cited by 169
Neurosteroids as regenerative agents in the brain: therapeutic implications
Brinton, R. D. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.31 · Cited by 169
Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease
Tarawneh, R. M., D’Angelo, G., Macy, E., Xiong, C., Carter, D. R., Cairns, N. J., Fagan, A. M., Head, D. M., Mintun, M. A., Ladenson, J. H., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22448 · Cited by 169
Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
McGrowder, D. A., Miller, F. G., Vaz, K., Nwokocha, C. R., Wilson-Clarke, C. F., Anderson, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 169
The emerging role of glutathione in Alzheimer’s disease
Saharan, S., & Mandal, P. K. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132483 · Cited by 168
APOE modifies the association between Aβ load and cognition in cognitively normal older adults
Kantarci, K., Lowe, V. J., Przybelski, S. A., Weigand, S. D., Senjem, M. L., Ivnik, R. J., Preboske, G. M., Roberts, R. O., Geda, Y. E., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31824365ab · Cited by 168
Self-citationTong, T., Gao, Q., Guerrero, R., Ledig, C., Chen, L., Rueckert, D., & Initiative, A. D. N. (2016) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2549363 · Cited by 167
Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?
Studart‐Neto, A., & Nitríni, R. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1003002 · Cited by 167
Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia
Seo, J., Kritskiy, O., Watson, L. A., Barker, S. J., Dey, D., Raja, W. K., Lin, Y.-T., Ko, T., Cho, S., Penney, J., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.0621-17.2017 · Cited by 156
Xu, H., & Remmen, H. V. (2021) · Skeletal Muscle · doi:10.1186/s13395-021-00280-7 · Cited by 167
Kanmert, D., Cantlon, A., Muratore, C., Jin, M., O’Malley, T. T., Lee, G. S., Young‐Pearse, T. L., Selkoe, D. J., & Walsh, D. M. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0387-15.2015 · Cited by 169
Smith, R. G., Pishva, E., Shireby, G. L., Smith, A. R., Roubroeks, J. A. Y., Hannon, E. J., Wheildon, G., Mastroeni, D., Gasparoni, G., Riemenschneider, M. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23243-4 · Cited by 176
Gray matter atrophy pattern in elderly with subjective memory impairment
Peter, J., Scheef, L., Abdulkadir, A., Boecker, H., Heneka, M., Wagner, M., Koppara, A., Klöppel, S., Jessen, F., & Initiative, A. D. N. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1764 · Cited by 165
Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., Chen, Q., Chen, H., Ma, F., An, Y., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b03644 · Cited by 166
Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine
Eid, A., Mhatre, I., & Richardson, J. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.005 · Cited by 164
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition
Vemuri, P., Weigand, S. D., Przybelski, S. A., Knopman, D. S., Smith, G. E., Trojanowski, J. Q., Shaw, L. M. J., DeCarli, C. S., Carmichael, O. T., Bernstein, M. A., et al. (2011) · Brain · doi:10.1093/brain/awr049 · Cited by 164
Self-citationTeixeira, A. L., Barbosa, I. G., Diniz, B. S., & Kümmer, A. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.111 · Cited by 164
Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET
Ossenkoppele, R., Tolboom, N., Foster‐Dingley, J. C., Adriaanse, S. F., Boellaard, R., Yaqub, M. M., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., Scheltens, P., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2102-3 · Cited by 164
Crean, S., Ward, A., Mercaldi, C. J., Collins, J. M., Cook, M. N., Baker, N. L., & Arrighi, H. M. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000321984 · Cited by 163
Indicators of amyloid burden in a population-based study of cognitively normal elderly
Mielke, M. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Roberts, R. O., Geda, Y. E., Swenson-Dravis, D. M., Boeve, B. F., Senjem, M. L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e2696 · Cited by 163
Self-citationNeuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection
Risacher, S. L., & Saykin, A. J. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185535 · Cited by 163
Alzheimer Disease and Its Growing Epidemic
Hickman, R. A., Faustin, A., & Wısnıewskı, T. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.009 · Cited by 163
Sundermann, E. E., Initiative, A. D. N., Biegon, A. R., Rubin, L. H., Lipton, R. B., Landau, S. M., & Maki, P. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160716 · Cited by 163
Nuclear factor‐kappa β as a therapeutic target for Alzheimer's disease
Jha, N. K., Jha, S. K., Kar, R., Nand, P., Swati, K., & Goswami, V. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14687 · Cited by 163
Sex-driven modifiers of Alzheimer risk
Rahman, A., Schelbaum, E., Hoffman, K., Diaz, I., Hristov, H., Andrews, R. D., Jett, S., Jackson, H. C., Lee, A., Sarva, H., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009781 · Cited by 163
Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging
Jagust, W. J., Landau, S. M., & Initiative, F. T. A. D. N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3266-12.2012 · Cited by 162
Self-citationEarly diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin
Carro, E., Bartolomé, F. B., Bermejo‐Pareja, F., Villarejo‐Galende, A., Molina, J. A., Ortiz-Romero, P. L., Calero, M., Rábano, A., Cantero, J. L., & Orive, G. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.04.002 · Cited by 162
Kester, M. I., Goos, J. D. C., Teunissen, C. E., Benedictus, M. R., Bouwman, F. H., Wattjes, M. P., Barkhof, F., Scheltens, P., & van der Flier, W. M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.754 · Cited by 161
Protas, H. D., Chen, K., Langbaum, J. B. S., Fleisher, A. S., Alexander, G. E., Lee, W., Bandy, D., de Leon, M. J., Mosconi, L., Buckley, S., et al. (2013) · JAMA Neurology · doi:10.1001/2013.jamaneurol.286 · Cited by 161
Self-citationAmyloid‐ß‐directed immunotherapy for Alzheimer's disease
Lannfelt, L., Relkin, N. R., & Siemers, E. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12168 · Cited by 161
Cosín‐Tomás, M., Antonell, A., Lladó, A., Alcolea, D. A., Fortea, J., Ezquerra, M., Lleó, A., Martı́, M. J., Pallàs, M., Sánchez‐Valle, R., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0088-8 · Cited by 161
Gupta, Y., Lama, R. K., Kwon, G., & Initiative, A. D. N. (2019) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2019.00072 · Cited by 161
Cortical tau deposition follows patterns of entorhinal functional connectivity in aging
Adams, J. N., Maass, A., Harrison, T. M., Baker, S. L., & Jagust, W. J. (2019) · eLife · doi:10.7554/elife.49132 · Cited by 160
Self-citationWijnands, J. M. A., Kingwell, E., Zhu, F., Zhao, Y., Högg, T., Stadnyk, K., Ekuma, O., Lu, X., Evans, C. D., Fisk, J. D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30076-5 · Cited by 160
Network localization of heterogeneous neuroimaging findings
Darby, R. R., Joutsa, J., & Fox, M. (2018) · Brain · doi:10.1093/brain/awy292 · Cited by 163
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 161
Biomarkers in dementia: clinical utility and new directions
Ahmed, R. M., Paterson, R. W., Warren, J. D., Zetterberg, H., O'Brien, J. T., Fox, N. C., Halliday, G. M., & Schott, J. M. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307662 · Cited by 159
Diagnosis and biomarkers of predementia in Alzheimer's disease
Forlenza, O. V., Diniz, B. S., & Gattaz, W. F. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-89 · Cited by 160
Potential benefits of adherence to the Mediterranean diet on cognitive health
Féart, C., Samieri, C., Allès, B., & Barberger‐Gateau, P. (2012) · Proceedings of The Nutrition Society · doi:10.1017/s0029665112002959 · Cited by 159
PET Approaches for Diagnosis of Dementia
Ishii, K. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3695 · Cited by 159
Riancho, J., Vázquez-Higuera, J. L., Pozueta, A., Lage, C., Kazimierczak, M., Bravo, M., Calero, M., Gonalezález, A., Rodríguez, E., Lleó, A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161179 · Cited by 159
Relationship between Exercise and Alzheimer’s Disease: A Narrative Literature Review
Meng, Q., Lin, M.-S., & Tzeng, I.-S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00131 · Cited by 158
Alzheimer’s Disease Pathogenesis: Role of Autophagy and Mitophagy Focusing in Microglia
Eshraghi, M., Adlimoghaddam, A., Mahmoodzadeh, A., Sharifzad, F., Yasavoli-Sharahi, H., Lorzadeh, S., Albensi, B. C., & Ghavami, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073330 · Cited by 158
CSF Aβ 42 predicts early-onset dementia in Parkinson disease
Alves, G. W., Lange, J., Blennow, K., Zetterberg, H., Andréasson, U., Førland, M. G. G., Tysnes, O., Larsen, J. O., & Pedersen, K. F. (2014) · Neurology · doi:10.1212/wnl.0000000000000425 · Cited by 158
Vascular burden and Alzheimer disease pathologic progression
Lo, R. Y., Jagust, W. J., Weiner, M., Aisen, P., Weiner, M., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1b9d · Cited by 156
Self-citationWolk, D. A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.153 · Cited by 156
Amyloid-β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis
Lucey, B. P., & Bateman, R. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.035 · Cited by 156
Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals
Berti, V., Murray, J., Davies, M., Spector, N. C., Tsui, W. H., Li, Y., Williams, S. K., Pirraglia, E., Vallabhajosula, S., McHugh, P. F., et al. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0534-0 · Cited by 156
MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease
Devanand, D. P., Bansal, R., Liu, J., Hao, X., Pradhaban, G., & Peterson, B. S. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.075 · Cited by 156
Giacomucci, G., Mazzeo, S., Bagnoli, S., Ingannato, A., Leccese, D., Berti, V., Padiglioni, S., Galdo, G., Ferrari, C., Sorbi, S., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11055-5 · Cited by 156
Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia
Risacher, S. L., & Saykin, A. J. (2013) · Seminars in Neurology · doi:10.1055/s-0033-1359312 · Cited by 155
Meta-Analysis of Plasma Amyloid-β levels in Alzheimer's Disease
Song, F., Poljak, A., Valenzuela, M., Mayeux, R. P., Smythe, G. A., & Sachdev, P. S. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101977 · Cited by 155
Alber, J., Goldfarb, D., Thompson, L. I., Arthur, E., Hernandez, K., Cheng, D., DeBuc, D. C., Cordeiro, F., Provetti‐Cunha, L., den Haan, J., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12006 · Cited by 154
Myhre, O., Utkilen, H., Duale, N., Brunborg, G., & Hofer, T. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/726954 · Cited by 154
Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review
Stephan, B. C. M., Minett, T., Pagett, E., Siervo, M., Brayne, C., & McKeith, I. G. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001909 · Cited by 154
Serial MRI and CSF biomarkers in normal aging, MCI, and AD
Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Aisen, P. S., Weiner, M., Petersen, R. C., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e7ca82 · Cited by 154
Self-citationLannfelt, L., Möller, C., Basun, H., Osswald, G., Sehlin, D., Satlin, A., Logovinsky, V., & Gellerfors, P. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt246 · Cited by 153
Schöll, M., Carter, S. F., Westman, E., Rodriguez‐Vieitez, E., Almkvist, O., Þórðardóttir, S., Wall, A. E., Graff, C., Långström, B., & Nordberg, A. K. (2015) · Scientific Reports · doi:10.1038/srep16404 · Cited by 153
Alzheimer’s disease: How metal ions define β-amyloid function
Kepp, K. P. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.05.007 · Cited by 154
Why Pleiotropic Interventions are Needed for Alzheimer's Disease
Frautschy, S. A., & Cole, G. M. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8137-1 · Cited by 152
Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects
Lim, H. K., Nebes, R. D., Snitz, B. E., Cohen, A. D., Mathis, C. A., Price, J. C., Weissfeld, L. A., Klunk, W. E., & Aizenstein, H. J. (2014) · Brain · doi:10.1093/brain/awu271 · Cited by 152
Chen, K. T., Gong, E., Macruz, F., Xu, J., Boumis, A., Khalighi, M. M., Poston, K. L., Sha, S. J., Greicius, M. D., Mormino, E. C., et al. (2020) · Radiology · doi:10.1148/radiol.2020202527 · Cited by 152
Wirth, M., Madison, C. M., Rabinovici, G. D., Oh, H., Landau, S. M., & Jagust, W. J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4409-12.2013 · Cited by 151
Self-citationSun, Y., Zhang, H., Zhang, X., Wang, W., Chen, Y., Cai, Z., Wang, Q., Wang, J., & Shi, Y. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102690 · Cited by 151
Graph theoretical framework of brain networks in multiple sclerosis: a review of concepts
Fleischer, V., Radetz, A., Ciolac, D., Muthuraman, M., Gonzalez-Escamilla, G., Zipp, F., & Groppa, S. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2017.10.033 · Cited by 151
Fjell, A. M., Sneve, M. H., Storsve, A. B., Grydeland, H., Yendiki, A., & Walhovd, K. B. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv102 · Cited by 151
Rotman, M., Welling, M. M., Bunschoten, A., de Backer, M. E., Rip, J., Nabuurs, R. J. A., Gaillard, P. J., van Buchem, M. A., van der Maarel, S. M., & van der Weerd, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.012 · Cited by 151
Mormino, E. C., Brandel, M. G., Madison, C. M., Marks, S. M., Baker, S. L., & Jagust, W. J. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr255 · Cited by 151
Self-citationStatins, cognition, and dementia-systematic review and methodological commentary
Power, M. C., Weuve, J., Sharrett, A. R., Blacker, D., & Gottesman, R. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.35 · Cited by 150
Cheng, Y.-W., Chen, T.-F., & Chiu, M.-J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s123428 · Cited by 150
Ganguli, M., Fu, B., Snitz, B. E., Hughes, T. F., & Chang, C. H. (2013) · Neurology · doi:10.1212/wnl.0b013e318295d776 · Cited by 150
Ferreira, D., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano‐Aguilar, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00047 · Cited by 153
Caroli, A., & Frisoni, G. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.024 · Cited by 150
Cogswell, P. M., Barakos, J. A., Barkhof, F., Benzinger, T. L. S., Jack, C. R., Poussaint, T. Y., Raji, C. A., Ramanan, V. K., & Whitlow, C. T. (2022) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7586 · Cited by 150
Self-citationSleep disturbances and dementia risk: a multicenter study
Sindi, S., Kåreholt, I., Johansson, L., Skoog, J., Sjöberg, L., Wang, H., Johansson, B., Fratiglioni, L., Soininen, H., Solomon, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.05.012 · Cited by 144
Ushering in the study and treatment of preclinical Alzheimer disease
Langbaum, J. B. S., Fleisher, A., Chen, K., Ayutyanont, N., Lopera, F. J., Quiroz, Y. T., Caselli, R. J., Tariot, P. N., & Reiman, E. M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.107 · Cited by 149
Fletcher, E. M., Raman, M. R., Huebner, P. A., Liu, A., Mungas, D., Carmichael, O. T., & DeCarli, C. S. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3263 · Cited by 149
Braak, H., Zetterberg, H., Tredici, K. D., & Blennow, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1139-0 · Cited by 148
Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 148
Self-citationKang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 147
Self-citationTADPOLE Challenge: Prediction of Longitudinal Evolution in Alzheimer's DiseasePreprint
Marinescu, R. V., Oxtoby, N. P., Young, A. L., Bron, E. E., Toga, A. W., Weiner, M. W., Barkhof, F., Fox, N. C., Klein, S., Alexander, D. C., et al. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1805.03909 · Cited by 148
Self-citationVellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147
Self-citationWolk (2012) · doi:10.1097/wco.0b013e328354ff0a · Cited by 147
Retracted: ‘Clinical trials in Alzheimer’s disease’: immunotherapy approaches
Delrieu, J., Ousset, P., Caillaud, C., & Vellas, B. J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07458.x · Cited by 147
Retracted
Metadata
- Authors
- Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q.
- Affiliations
- Mayo Clinic (US)
- University of California, Berkeley (US)
- University of Pennsylvania (US)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Corresponding author
- Jack, Clifford R
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 9
- Issue
- 1
- Pages
- 119-128
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC2819840
- OpenAlex
- W2167840686
- Cited by
- 4,806
- References
- 119
- Citations by year
- 2026: 273 · 2025: 317 · 2024: 278 · 2023: 259 · 2022: 308 · 2021: 321 · 2020: 359 · 2019: 303 · 2018: 267 · 2017: 283 · 2016: 265 · 2015: 273 · 2014: 335 · 2013: 337 · 2012: 301
- FWCI
- 127.41
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (AG11378)
- National Institute on Aging
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, amyloid PET, tau protein, brain atrophy, FDG-PET, synaptic dysfunction, neurodegeneration, disease stage, biomarkers, cognitive decline
- MeSH terms
- Aging, Alzheimer Disease, Brain, Cognition Disorders, Humans, Magnetic Resonance Imaging, Models, Neurological, Time Factors, Signal Transduction, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Positron-Emission Tomography, Apolipoprotein E4, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
